Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase.
about
RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A Virus.Generation of small molecules to interfere with regulated necrosis.Lysis of human neutrophils by community-associated methicillin-resistant Staphylococcus aureus.Biomarkers for the detection of necroptosis.RIPK3 Restricts Viral Pathogenesis via Cell Death-Independent Neuroinflammation.Complex Pathologic Roles of RIPK1 and RIPK3: Moving Beyond Necroptosis.Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis.Life after death: RIP1 and RIP3 move beyond necroptosis.6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury.Drilling into RIP1 biology: what compounds are in your toolkit?t-BuOOH induces ferroptosis in human and murine cell lines.Identification of an antibody-based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues.RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680).When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157.RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism.Ubiquitin-Mediated Regulation of RIPK1 Kinase Activity Independent of IKK and MK2.The role of necroptosis in the treatment of diseases.Caspase-8 Collaborates with Caspase-11 to Drive Tissue Damage and Execution of Endotoxic Shock
P2860
Q38763365-BC8DCA3E-5382-45C7-9107-DF8A2DDCD0A1Q38799144-0EC3AE4E-6256-446D-ADC0-780663409D9BQ38803317-78FE78BF-1AB2-4697-A07C-E967BFC131BDQ38804928-244D3075-9144-4BE1-B364-BB8999419448Q38862204-793C5E55-3F9D-4AD6-9E8D-5937004AB3FEQ39105381-AFAD040D-5AC8-4987-9531-75BE72D3403EQ40132104-E03D5A21-6BBE-444A-BE76-321D8E1FBE7CQ40566512-77CF5C48-C426-461E-8EDA-0964040DEF27Q41919743-4315C767-9044-4F2B-840D-E9721F3D2D0AQ43167136-FEC1FAA6-36D8-482E-A903-4602432A3F39Q46295503-CB2C8486-3E11-4197-8CB5-10BB91D47D1AQ47115973-2280D37E-8D0C-4A2C-8DCC-8117612E94B6Q49025576-B44D01AE-605D-46D3-85FD-249101351B66Q49099457-4DC67A7A-2BCB-434A-8778-D8BBB2515539Q49571560-015FB3FE-4DF1-49A2-B399-ABB430EA3C69Q49920451-1B7A67B2-DA38-46D7-A46C-00A01331E050Q55386853-DAB6402A-00A5-494C-9133-6208EF19AD9EQ57099957-0154B53E-CB97-4FD5-AE63-DE6E1D4D60F4
P2860
Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Characterization of GSK'963: a ...... tive inhibitor of RIP1 kinase.
@en
Characterization of GSK'963: a ...... tive inhibitor of RIP1 kinase.
@nl
type
label
Characterization of GSK'963: a ...... tive inhibitor of RIP1 kinase.
@en
Characterization of GSK'963: a ...... tive inhibitor of RIP1 kinase.
@nl
prefLabel
Characterization of GSK'963: a ...... tive inhibitor of RIP1 kinase.
@en
Characterization of GSK'963: a ...... tive inhibitor of RIP1 kinase.
@nl
P2093
P2860
P1433
P1476
Characterization of GSK'963: a ...... tive inhibitor of RIP1 kinase.
@en
P2093
C Capriotti
D Wisnoski
M Ouellette
M Schaeffer
P2860
P2888
P356
10.1038/CDDISCOVERY.2015.9
P577
2015-07-27T00:00:00Z
P5875
P6179
1030069173